J-S Doly1, E Lorian2, I Desormais2, J Constans2, A Bura Rivière2, P Lacroix2. 1. Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France. Electronic address: jeansimon.doly@gmail.com. 2. Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
Abstract
OBJECTIVES: To assess the prevalence and the association between aspirin resistance in critical limb ischemia patients using the VerifyNow® bed-side platelet test, and occurrence of cardiovascular morbidity and/or death at one year. MATERIALS AND METHODS: National multicenter prospective observational study related to COPART II centers. From 2010 through 2014, 64 subjects hospitalized for critical limb ischemia and already treated by aspirin before the VerifyNow® test were included. A VerifyNow® test>550 ARU was defined as aspirin resistance. Critical limb ischemia was defined according to the TASC I criteria. The primary outcome was a composite including death, acute coronary syndrome, stroke and major amputation during the one-year follow-up period. RESULTS: In all, 9/64 patients were aspirin resistant, the status was confirmed in one case. The prevalence of aspirin resistance was 14.06%. There was no significant difference between aspirin resistant and aspirin non-resistant groups in terms of cardiovascular history and glycemia status. Neither was there significant difference between the two groups in terms of survival. CONCLUSION: Aspirin resistance was not predictive of poorer survival in critical limb ischemia patients. However, our population was limited. Considering that a clear definition of aspirin resistance and standardized diagnostic tests are lacking, complementary studies might be useful. Copyright Â
OBJECTIVES: To assess the prevalence and the association between aspirin resistance in critical limb ischemiapatients using the VerifyNow® bed-side platelet test, and occurrence of cardiovascular morbidity and/or death at one year. MATERIALS AND METHODS: National multicenter prospective observational study related to COPART II centers. From 2010 through 2014, 64 subjects hospitalized for critical limb ischemia and already treated by aspirin before the VerifyNow® test were included. A VerifyNow® test>550 ARU was defined as aspirin resistance. Critical limb ischemia was defined according to the TASC I criteria. The primary outcome was a composite including death, acute coronary syndrome, stroke and major amputation during the one-year follow-up period. RESULTS: In all, 9/64 patients were aspirin resistant, the status was confirmed in one case. The prevalence of aspirin resistance was 14.06%. There was no significant difference between aspirin resistant and aspirin non-resistant groups in terms of cardiovascular history and glycemia status. Neither was there significant difference between the two groups in terms of survival. CONCLUSION:Aspirin resistance was not predictive of poorer survival in critical limb ischemiapatients. However, our population was limited. Considering that a clear definition of aspirin resistance and standardized diagnostic tests are lacking, complementary studies might be useful. Copyright Â
Keywords:
Artériopathie oblitérante des membres inférieurs; Aspirin resistance; COPART; Critical limb ischemia; Ischémie critique des membres inférieurs; Peripheral arterial disease; Résistance à l’aspirine; VerifyNow(®) Aspirin